A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage.

Abstract

COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.

• Authors: Yogendra Singh, Neeraj Kumar Fuloria, Shivkanya Fuloria, Vetriselvan Subramaniyan, Waleed Hassan Almalki, Fahad A Al-Abbasi, Imran Kazmi, Sobhit Singh Rajput, Nirmal Joshi, Gaurav Gupta
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 88 Issue 8 Pg. 3562-3565 (08 2022) ISSN: 1365-2125 [Electronic] England
• PMID: 35352842 (Publication Type: Journal Article)
• Copyright: © 2022 British Pharmacological Society.

Chemical References

• Aminopyridines
• Benzamides
• Cyclopropanes
• Phosphodiesterase 4 Inhibitors
• Roflumilast

Topics

• Aged
• Aminopyridines (adverse effects)
• Benzamides
• Cyclopropanes (adverse effects)
• Humans
• Inflammation (drug therapy)
• Phosphodiesterase 4 Inhibitors (adverse effects)
• SARS-CoV-2
• COVID-19 Drug Treatment